Literature DB >> 15224360

Vasoactive factors in sickle cell disease: in vitro evidence for endothelin-1-mediated vasoconstriction.

Sitki Ergul1, Chris Y Brunson, Jim Hutchinson, Amany Tawfik, Abdullah Kutlar, R Clinton Webb, Adviye Ergul.   

Abstract

While systemic plasma endothelin-1 (ET-1) levels are increased during acute crisis in sickle cell disease, the relative levels of potent vasoactive factors that contribute to the regulation of vascular function, such as ET-1, NO, and cell-free hemoglobin, during the course of periodic vaso-occlusive episodes remain unclear. Moreover, whether and to what extent sickling-induced release of ET-1 alters vascular tone is not completely understood. To investigate the sequential changes in circulating vasoactive factors, we measured plasma ET-1, NO metabolites (NOx), and cell-free hemoglobin (Hb) before (steady-state), during (crisis), and after a vaso-occlusive (post-crisis) episode. Steady-state ET-1 levels (fmol/mL) increased from 2.3 +/- 0.4 to 11.0 +/- 1.4 and 4.2 +/- 1.0 during crisis and post-crisis periods, respectively. There was no significant difference in plasma NOx levels. Cell-free Hb levels were significantly higher in sickle cell patients in all phases as compared to the control group, and especially during crisis cell-free Hb levels were elevated by 4-fold (209,000 +/- 31,000 vs. 46,000 +/- 5,300 ng/mL in steady-state). Conditioned medium from human pulmonary artery endothelial cells exposed to sickled erythrocytes prepared by deoxygenation induced contraction of aortic rings, and this effect was blocked by an ET(A) receptor antagonist. These findings indicate that ET-1 is the predominant contractile factor released by cultured endothelial cells upon exposure to deoxygenated sickled SS erythrocytes and ET-1-NO-NO scavenger balance is altered in favor of vasoconstriction during an acute episode in SCD. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15224360     DOI: 10.1002/ajh.20107

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  23 in total

1.  Cardiopulmonary complications of sickle cell disease: role of nitric oxide and hemolytic anemia.

Authors:  Mark T Gladwin; Gregory J Kato
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2005

2.  Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease.

Authors:  Gregory J Kato; Vicki McGowan; Roberto F Machado; Jane A Little; James Taylor; Claudia R Morris; James S Nichols; Xunde Wang; Mirjana Poljakovic; Sidney M Morris; Mark T Gladwin
Journal:  Blood       Date:  2005-11-15       Impact factor: 22.113

3.  RGS4, a GTPase activator, improves renal function in ischemia-reperfusion injury.

Authors:  Andrew M Siedlecki; Xiaohua Jin; Winston Thomas; Keith A Hruska; Anthony J Muslin
Journal:  Kidney Int       Date:  2011-03-16       Impact factor: 10.612

4.  Individuals with sickle cell disease have a significantly greater vasoconstriction response to thermal pain than controls and have significant vasoconstriction in response to anticipation of pain.

Authors:  Maha Khaleel; Mammen Puliyel; Payal Shah; John Sunwoo; Roberta M Kato; Patjanaporn Chalacheva; Wanwara Thuptimdang; Jon Detterich; John C Wood; Jennie Tsao; Lonnie Zeltzer; Richard Sposto; Michael C K Khoo; Thomas D Coates
Journal:  Am J Hematol       Date:  2017-08-17       Impact factor: 10.047

5.  Endothelin-A Receptor Antagonism Retards the Progression of Murine Sickle Cell Nephropathy.

Authors:  Karl A Nath; Zvonimir S Katusic
Journal:  J Am Soc Nephrol       Date:  2017-04-25       Impact factor: 10.121

6.  Pulmonary hypertension in hemolytic disorders: pulmonary vascular disease: the global perspective.

Authors:  Roberto F Machado; Mark T Gladwin
Journal:  Chest       Date:  2010-06       Impact factor: 9.410

7.  Atherosclerosis in sickle cell disease - a review.

Authors:  Mohamed A Elsharawy; Khaled M Moghazy; Mohamed A Shawarby
Journal:  Int J Angiol       Date:  2009

8.  Circulating cell membrane microparticles transfer heme to endothelial cells and trigger vasoocclusions in sickle cell disease.

Authors:  Stéphane M Camus; João A De Moraes; Philippe Bonnin; Paul Abbyad; Sylvain Le Jeune; François Lionnet; Laurent Loufrani; Linda Grimaud; Jean-Christophe Lambry; Dominique Charue; Laurent Kiger; Jean-Marie Renard; Claire Larroque; Hervé Le Clésiau; Alain Tedgui; Patrick Bruneval; Christina Barja-Fidalgo; Antigoni Alexandrou; Pierre-Louis Tharaux; Chantal M Boulanger; Olivier P Blanc-Brude
Journal:  Blood       Date:  2015-03-31       Impact factor: 22.113

9.  Novel small molecule therapeutics for sickle cell disease: nitric oxide, carbon monoxide, nitrite, and apolipoprotein A-I.

Authors:  Gregory J Kato
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2008

10.  Modulation of pain in pediatric sickle cell disease: understanding the balance between endothelin mediated vasoconstriction and apelin mediated vasodilation.

Authors:  Terika P Smith; Alyssa M Schlenz; Jeffrey C Schatz; Rangan Maitra; Sarah M Sweitzer
Journal:  Blood Cells Mol Dis       Date:  2014-11-26       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.